← Eichor
Condition: Recurrent Burkitt Leukemia Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Recurrent Burkitt Leukemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors
Phase 1/Phase 2 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06503094A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic
Phase 1 · 8 location(s) · Autolus Limited · NCT06173518Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Phase 1/Phase 2 · 19 location(s) · Cellectis S.A. · NCT04150497AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Phase 1 · 1 location(s) · Stanford University · NCT06340737A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relap
Phase 1 · 8 location(s) · Shanghai Pharmaceutical Group Biological Therapy Technology · NCT06927466Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL
Phase 1/Phase 2 · 1 location(s) · Kara Yakhteh Tajhiz Azma Company · NCT06635330Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT01371630UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
Phase 1/Phase 2 · 1 location(s) · University of Colorado, Denver · NCT04544592CAR-T Cell Therapy for ALL
EARLY_Phase 1 · 1 location(s) · Dr. Zaineb Akram · NCT07695012CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leuk
Phase 1 · 1 location(s) · St. Jude Children's Research Hospital · NCT06777979Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT075235553'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma
Phase 1 · 1 location(s) · Institute of Hematology and Blood Transfusion, Czech Republi · NCT05054257Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, o
Phase 2 · 278 location(s) · National Cancer Institute (NCI) · NCT03739814Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06287229Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refrac
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT07133997Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
NA · 1 location(s) · Anhui Provincial Hospital · NCT06961669Study of Out of Specification for Tisagenlecleucel
Phase 3 · 54 location(s) · Novartis Pharmaceuticals · NCT04094311Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Ly
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT03136146Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Phase N/A · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137643Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
Phase 1 · 1 location(s) · University of Michigan Rogel Cancer Center · NCT07532525CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors
Phase 1/Phase 2 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06735495CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A
Phase 2 · 2 location(s) · KK Women's and Children's Hospital · NCT05648019CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL
Phase 1 · 1 location(s) · University of Colorado, Denver · NCT06559189CAV Regimen for R/R Ph- B-ALL
NA · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT05657652A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acu
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT04546399CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05442515NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)
Phase 2/Phase 3 · 4 location(s) · Health Institutes of Turkey · NCT07502118Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Mali
Phase 1 · 2 location(s) · Sumithira Vasu · NCT05418088
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.